On Jul. 29, 2020, Regeneron announced that the Biomedical Advanced Research and Development Authority (BARDA) had entered into an agreement to procure REGN-EB3 as part of the HHS’ goal of building national preparedness for public health emergencies.

Contingent on U.S. Food and Drug Administration (FDA) approval, Regeneron expected to deliver an established number of treatment doses over the course of six years and receive compensation of approximately $10 million in 2021 and an average of $67 million per year for each of the next five years (2022-2026).

In 2019, the randomized controlled PALM clinical trial conducted in the Democratic Republic of the Congo was stopped early when preliminary results showed that REGN-EB3 crossed the pre-specified superiority threshold for preventing death compared to the control arm, ZMapp^®. REGN-EB3 demonstrated superior efficacy compared to ZMapp across multiple measures, including reduced mortality and fewer days until the Ebola virus was no longer detected in the bloodstream. During the trial, there were three serious adverse events for REGN-EB3, compared to seven for ZMapp.